chidamide + tislelizumab + anlotinib

This is a combination regimen of three drugs with distinct mechanisms of action, used primarily in oncology clinical trials: - **Chidamide** is a selective histone deacetylase inhibitor (HDACi) that modulates gene expression by inhibiting histone deacetylases, leading to cell cycle arrest and apoptosis in cancer cells. - **Tislelizumab** is a humanized IgG4 monoclonal antibody targeting the programmed death 1 (PD‑1) receptor on T cells. By blocking PD‑1, it enhances anti-tumor immune responses. - **Anlotinib** is an oral multi-targeted tyrosine kinase inhibitor that inhibits angiogenesis and tumor growth by targeting vascular endothelial growth factor receptors 2 and 3 (VEGFR2/3), fibroblast growth factor receptors 1–4 (FGFR1–4), platelet-derived growth factor receptors α/β (PDGFRα/β), c-Kit, and Ret. The combination aims to synergistically inhibit tumor proliferation through epigenetic modulation, immune checkpoint blockade, and antiangiogenic effects. It has been investigated in clinical trials for various cancers including non-small cell lung cancer and extranodal NK/T-cell lymphoma[3][5][6][7].

Brand names

chidamide (Epidaza)tislelizumab (Baizean)anlotinib (Catequentinib)

Other names

chidamide + tislelizumab + anlotinib